Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same

The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the β-amyloid protein (Aβ) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of Aβ in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism.

COMPOSITE OF SILVER NANOPARTICLE AND LAYERED INORGANIC CLAY FOR INHIBITING GROWTH OF SILVER-RESISTANT BACTERIA

The present invention provides a composite of spherical silver nanoparticles and layered inorganic clay. This composite can effectively inhibit the growth of silver-resistant bacteria. The layered inorganic clay serves as carriers of the silver nanoparticles and disperses them. The composite has a particle size of about 5 nm to 100 nm. The silver nanoparticles can be dispersed in an organic solvent or water. 1. A composite of silver nanoparticles (AgNPs) and inorganic clay for inhibiting growth of silver-resistant bacteria , the composite comprising AgNPs and layered inorganic clay nanoparticles , wherein the composite has a particle size ranging from 5 nm to 100 nm , the layered inorganic clay has an aspect ratio (width/thickness ratio) of about 10 to 100 ,000 and serves as carriers of the AgNPs , the ratio of ionic equivalent of the AgNPs to cation exchanging equivalent (CEC) of the layered inorganic clay (Ag/CEC) ranges from 0.1/1 to 200/1 , and the AgNPs/clay weight ratio ranges from 1/99 to 99/1.2. The composite of claim 1 , wherein the silver-resistant bacteria are multi-silver-resistant bacteria.3Acinetobacter baumanniiEscherichia coli.. The composite of claim 1 , wherein the silver-resistant bacteria are silver-resistant or4. The composite of claim 1 , wherein the layered inorganic clay has an aspect ratio of about 100 to 1 claim 1 ,000.5. The composite of claim 1 , wherein the layered inorganic clay is bentonite claim 1 , laponite claim 1 , montmorillonite claim 1 , synthetic mica claim 1 , kaolin claim 1 , talc claim 1 , attapulgite clay claim 1 , vermiculite or double hydroxide (LDH) nanoparticles.6. The composite of claim 1 , wherein the layered inorganic clay is nanosilicate platelets or bentonite.7. The composite of claim 1 , wherein the AgNPs/clay weight ratio is about 1/99 to 20/80.8. The composite of claim 1 , wherein the AgNPs/clay weight ratio is about 3/97 to 10/90.9. A solution for inhibiting growth of silver-resistant bacteria claim 1 , the ...

Method for controlling toxicity of metallic particle and low-toxicity composite of metallic nanoparticle and inorganic clay

The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets.

Method for neuroepithelial cells differentiation from pluripotent stem cells and medium using same

The present invention discloses a neural induction medium comprising Wnt-signal agonist, TGFβ-signal inhibitor and FGF-signal agonist for inducing neural differentiation. The neural induction medium used in a culture system is capable for inducing the neural differentiation of stem cells into neuroepithelial cells which are useful for the clinical applications. Therein, the neuroepithelial cells can further differentiate into mature neurons for the practical applications including regeneration medicine and drug discovery for neural disorders. 1. A neural induction medium comprises Wnt-signal agonist , TGFβ-signal inhibitor and FGF-signal agonist.2. The neural induction medium of claim 1 , wherein the Wnt-signal agonist is selected from the group consisting of Wnt ligands and GFK-3β inhibitor (glycogen synthase kinase 3β inhibitor) BIO (6-bromoindirubin-3′-oxime).3. The neural induction medium of claim 1 , wherein the Wnt-signal agonist is GFK-3β inhibitor BIO with the working concentration between 0.05 μM to 50 μM.4. The neural induction medium of claim 2 , wherein the Wnt-signal agonist is GFK-3β inhibitor BIO with the working concentration between 0.05 μM to 50 μM.5. The neural induction medium of claim 1 , wherein the TGFβ-signal inhibitor is selected from the group consisting of bone morphogenetic protein inhibitor (BMP inhibitor) claim 1 , Chordin claim 1 , Noggin claim 1 , Dorsomorphin claim 1 , Smad1 inhibitor claim 1 , Activin/Nodal receptor inhibitor SB431542 claim 1 , and Smad2/3-inhibitor.6. The neural induction medium of claim 1 , wherein the TGFβ-signal inhibitor is Activin/Nodal receptor inhibitor SB431542 with working concentration between 1 μM to 100 μM.7. The neural induction medium of claim 5 , wherein the TGFβ-signal inhibitor is Activin/Nodal receptor inhibitor SB431542 with working concentration between 1 μM to 100 μM.8. The neural induction medium of claim 1 , wherein the FGF-signal agonist is selected from the group consisting of FGF2 claim 1 ...

METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY

The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nanosilicate platelets. 1. A method for producing a composite of metallic nanoparticles and inorganic clay , comprising a step of mixing and reacting metallic particles , layered inorganic clay and a reducing agent to generate the composite having a size of 5 to 100 nm , wherein the weight ratio of the metallic nanoparticles to the layered inorganic clay ranges from 0.1/99.9 to 6.0/94.0; the layered inorganic clay has an aspect ranging from 10 to 100 ,000 and serves as carriers of the metallic nanoparticles.2. The method of claim 1 , wherein the weight ratio of the metallic nanoparticles to the layered inorganic clay ranges from 0.5/99.5 to 3/97.3. The method of claim 1 , wherein the weight ratio of the metallic nanoparticles to the layered inorganic clay ranges from 0.5/99.5 to 2/98.4. The method of claim 1 , wherein the metallic particles are gold claim 1 , silver claim 1 , copper or iron.5. The method of claim 1 , wherein the layered inorganic clay is nanosilicate platelets claim 1 , montmorillonite (MMT) claim 1 , bentonite claim 1 , laponite claim 1 , synthetic mica claim 1 , kaolinite claim 1 , talc claim 1 , attapulgite clay claim 1 , vermiculite or layered double hydroxides (LDH).6. The method of claim 1 , wherein the reducing agent is methanol claim 1 , ethanol claim 1 , propanol claim 1 , butanol claim 1 , formaldehyde claim 1 , ethylene glycol claim 1 , or propylene glycol claim 1 , butanediol claim 1 , glycerine claim 1 , PVA (polyvinyl alcohol) claim 1 , PEG ( ...

Method of using composite of silver nanoparticles and nanosilicate platelets to inhibit growth of silver-resistant bacteria

The present invention provides a method of using a composite of spherical silver nanoparticles and layered inorganic clay, in particular nanosilicate platelets, for inhibiting the growth of silver-resistant bacteria. The layered inorganic clay serves as carriers of the silver nanoparticles and disperses them. The composite has a particle size of about 5 nm to 100 nm. The silver nanoparticles can be dispersed in an organic solvent or water.

USE OF COMPOSITION FOR REDUCING OR PREVENTING CELL AGING OR REPAIRING CELL WITH DAMAGED MITOCHONDRIA, METHOD OF PREPARING COMPOSITION FOR CELL REPAIRING, CELL REPAIRING METHOD AND METHOD OF SUPPLYING MITOCHONDRIA INTO CELL

A composition with exogenous mitochondria as active ingredients, and a use thereof and a cell repairing method therefor. The composition includes exogenous mitochondria and at least one pharmaceutically or cosmetically acceptable carrier. The composition may further include an adjuvant, and the adjuvant is selected from a group consisting of serum, plasma, complement and at least the above two ingredients. The exogenous mitochondria are obtained from cells by a centrifugal purification method. 1. A use of a composition for reducing or preventing aging of cell , or repairing a cell with damaged mitochondria , the composition comprising:exogenous mitochondria with C3 complement; andat least one pharmaceutically or cosmetically acceptable carrier.2. The use of claim 1 , wherein there is no serum and plasma in the composition.3. The use of claim 1 , wherein the exogenous mitochondria with C3 complement is the exogenous mitochondria treated by C3 complement in a concentration of 1 μg/mL to 20 μg/mL.4. The use of claim 1 , wherein the cell is skin cell.5. The use of claim 1 , wherein the cell is fibroblast.6. The use of claim 1 , wherein the cell is human umbilical vascular endothelial cell.7. A method of preparing a composition for cell repairing claim 1 , comprising:mixing exogenous mitochondria and C3 complement to obtain a mixture; andcentrifuging the mixture to remove redundant C3 complement to obtain a composition comprising the exogenous mitochondria with C3 complement.8. The method of claim 7 , wherein there is no serum and plasma in the composition.9. The method of claim 7 , wherein C3 complement mixed with the exogenous mitochondria has a concentration of 1 μg/mL to 20 μg/mL.10. A cell repairing method claim 7 , comprising:{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'preparing a composition for cell repairing by the method of ; and'}administrating an effective dosage of the composition into an individual so that the exogenous mitochondria with C3 ...

Culture medium and method for inducing differentiation of pluripotent stem cells into neuroepithelial cells

The present invention discloses a culture medium and method for inducing differentiation of pluripotent stem cells into neuroepithelial cells. The culture medium comprises at least two agents for neural induction, wherein the agents includes a Wnt signal agonist and a Smad2/3 inhibitor and the culture medium is a feeder free culture. The method is to culture pluripotent stem cells in the culture medium to differentiate into neuroepithelial cells. The neuroepithelial cells can further differentiate into mature neurons for practical applications, including regeneration medicine and drug discovery for neural disorders. 1. A culture medium for inducing differentiation of pluripotent stem cells into neuroepithelial cells comprising at least two agents for neural induction , wherein the agents include a Wnt signal agonist and a Smad2/3 inhibitor and the culture medium is a feeder free culture.2. The culture medium according to claim 1 , wherein the Wnt signal agonist is a GSK-3β inhibitor claim 1 ,3. The culture medium according to claim 2 , wherein the Wnt signal agonist is BIO and the Smad2/3 inhibitor is SB431542.4. The culture medium according to claim 1 , wherein a BMP signaling inhibitor is absent from the culture medium.5. The culture medium according to claim 4 , wherein the BMP signaling inhibitor is selected from a group consisting of noggin and dorsomorphin (compound C).6. The culture medium according to claim 1 , wherein the concentration of BIO ranges from 0.05 μM to 50 μM and the concentration of SB431542 ranges from 1 μM to 100 μM.7. The culture medium according to claim 1 , wherein the culture medium further includes a growth factor.8. The culture medium according to claim 7 , wherein the growth factor is FGF signal agonist.9. The culture medium according to claim 8 , wherein the growth factor is FGF2.10. The culture medium according to claim 8 , wherein the concentration of FGF signal agonist ranges from 1 ng/ml to 100 ng/ml.11. An additive to a culture ...

METHOD AND PHARMACEUTICAL COMPOSITION FOR CONTINUOUSLY MAINTAINING GROWTH OF A MOTOR NEURON PROGENITOR CELL

This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron. 1. A method for continuously maintaining growth of a motor neuron progenitor cell , comprising culturing a motor neuron progenitor cell under a culture condition constructed by an olfactory ensheathing cell to make the motor neuron progenitor cell maintain the ability to self-renewal and differentiate to a mature motor neuron cell.2. The method for continuously maintaining growth of a motor neuron progenitor cell according to claim 1 , wherein the culture condition is a culture media including the olfactory ensheathing cell.3. The method for continuously maintaining growth of a motor neuron progenitor cell according to claim 1 , wherein the culture condition is an OEC-free media with pre-treatment of the olfactory ensheathing cell.4. The method for continuously maintaining growth of a motor neuron progenitor cell according to claim 2 , wherein the motor neuron progenitor cell is cultured in low density.5. The method for continuously maintaining growth of a motor neuron progenitor cell according to claim 3 , wherein the motor neuron progenitor cell is cultured in high density.6. The method for continuously maintaining growth of a motor neuron progenitor cell according to claim 2 , wherein seeding at least ...

APPLICATIONS OF BUTYLIDENEPHTHALIDE

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood. 1. A kit for promoting the differentiation of a stem cell into a brown-like adipose cell , comprising the following components:(1) a conditional medium, comprising a basic medium and an ingredient capable of inducing the differentiation of a stem cell into an adipose cell; and(2) butylidenephthalide (BP).2. The kit as claimed in claim 1 , wherein the ingredient is selected from the group consisting of rosiglitazone claim 1 , insulin claim 1 , 3-isobutyl-1-methylxanthine (IBMX) claim 1 , dexamethasone claim 1 , and combinations thereof.3. A method for inhibiting the accumulation of white fat and/or promoting the conversion of white fat into brown fat claim 1 , comprising administering to a subject in need an effective amount of butylidenephthalide (BP).4. A method for inhibiting the accumulation of white fat claim 1 , promoting the conversion of white fat into brown fat claim 1 , inhibiting weight gain and/or reducing the contents of triglycerides claim 1 , glucose and total cholesterol in blood claim 1 , comprising administering to a subject in need an effective amount of butylidenephthalide (BP) claim 1 , and the butylidenephthalide (BP) is administered with at least one of a mesenchymal stem cell and a brown-like adipose cell.5. The method as claimed in claim 4 , which is for anti-obesity and/or preventing metabolic syndrome associated with obesity.6. The method as claimed in claim 5 , wherein the metabolic syndrome is at least one of diabetes mellitus claim 5 , cerebrovascular disease claim 5 , ...

Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same

The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the β-amyloid protein (Aβ) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of Aβ in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism. 1. A method for promoting the hair growth , comprising administrating a topical composition for promoting the hair growth to the skin of a subject , wherein the topical composition comprises an effective amount of butylidenephthalide (Bdph) or an analog thereof , and a pharmaceutically or cosmetically acceptable carrier.2. The method according to claim 1 , wherein the skin is a region having hair follicles.3. The method according to claim 1 , wherein the topical composition for promoting the hair growth is directly applied onto the skin of the subject.4. The method according to claim 1 , wherein the topical composition for promoting the hair growth is sprayed onto the skin of the subject.5. The method according to claim 1 , wherein the concentration of the compound of butylidenephthalide (Bdph) is from 1 μM to 1 mM.6. The ...

COMPOSITION WITH EXOGENOUS MITOCHONDRIA AS ACTIVE INGREDIENTS AND USE THEREOF AND CELL REPAIRING METHOD THEREFOR

A composition with exogenous mitochondria as active ingredients, and a use thereof and a cell repairing method therefor. The composition includes exogenous mitochondria and at least one pharmaceutically or cosmetically acceptable carrier. The composition may further include an adjuvant, and the adjuvant is selected from a group consisting of serum, plasma, complement and at least the above two ingredients. The exogenous mitochondria are obtained from cells by a centrifugal purification method. 1. A composition , comprising:exogenous mitochondria; andat least one pharmaceutically or cosmetically acceptable carrier.2. The composition of claim 1 , further comprising an adjuvant claim 1 , and the adjuvant being selected from a group consisting of serum claim 1 , plasma claim 1 , complement and a combination of at least two of the above ingredients.3. The composition of claim 1 , wherein the exogenous mitochondria are extracted from cells.4. The composition of claim 1 , wherein the exogenous mitochondria are obtained from cell by a centrifugal purification method.5. A use of the composition of for reducing or preventing aging of skin cells.6. A use of the composition of for repairing a cell with damaged mitochondria.7. A cell repairing method comprising administrating an effective dosage of exogenous mitochondria into an individual so that the exogenous mitochondria enter a cell and substitute aged mitochondria or damaged mitochondria.8. The anti cell aging method of claim 7 , wherein before the exogenous mitochondria are administrated into the individual claim 7 , the exogenous mitochondria are pretreated by at least one ingredient selected from a group consisting of serum claim 7 , plasma claim 7 , and complement. This non-provisional application is the U.S. National Stage of InternationalApplication No. PCT/CN2014/087975, filed on Sep. 30, 2014, published in Chinese, the entire contents of which are hereby incorporated by reference.The disclosure relates to a method ...

METHOD FOR DELAYING THE ONSET OF PULMONARY FIBROSIS OR TREATING PULMONARY FIBROSIS

The present invention relates to a method of delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis, comprising administering to a subject in need an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: 7. The method as claimed in claim 1 , which is for enhancing the anti-oxidation capability of alveolar cells claim 1 , increasing the survival rate of alveolar cells claim 1 , alleviating the oxidative stress-induced injury to the pulmonary tissue claim 1 , inhibiting the pulmonary fibroblast to myofibroblast conversion claim 1 , inhibiting the epithelial-mesenchymal transition of pulmonary fibroblasts and/or inhibiting the overexpression of extracellular matrix.8. The method as claimed in claim 1 , which is for regulating the immune response in pulmonary tissue claim 1 , alleviating the thickening of alveolar wall tissue claim 1 , alleviating the abnormal infiltration of pulmonary cell and/or alleviating the decrease in pulmonary function.9. The method as claimed in claim 1 , which is for regulating the expression of Sox2 protein in cells claim 1 , inhibiting the expression of collagen and inhibiting the expression of TGF-β protein.10. The method as claimed in claim 1 , wherein the active ingredient is administered at an amount ranging from about 1 mg (as the compound of formula (I))/kg-body weight to about 500 mg (as the compound of formula (I))/kg-body weight per day.11. The method as claimed in claim 1 , wherein the active ingredient is administered at an amount ranging from about 5 mg (as the compound of formula (I))/kg-body weight to about 200 mg (as the compound of formula (I))/kg-body weight per day.12. The method as claimed in claim 1 , wherein the active ingredient is administered at an amount ranging from about 10 mg (as the compound of formula (I))/kg-body weight to about 100 mg (as the compound ...

USE OF Z-BUTYLIDENEPHTHALIDE IN ACTIVATING AUTOIMMUNE SYSTEM

A method for at least one of activating autoimmune system and treating cancer is provided. The method comprises administering to a subject in need an effective amount of Z-butylidenephthalide and an effective amount of monocytes. 1. A method for at least one of activating autoimmune system and treating cancer , comprising administering to a subject in need an effective amount of Z-butylidenephthalide (Z-BP) and an effective amount of monocytes.2. The method as claimed in claim 1 , wherein the monocyte is selected from the group consisting of an autologous monocyte claim 1 , an exogenous monocyte claim 1 , and combinations thereof.3. The method as claimed in claim 1 , wherein the monocyte is at least one of lymphatic cells claim 1 , myeloid cell claim 1 , phagocyte claim 1 , and antigen presenting cell.4. The method as claimed in claim 1 , wherein the monocyte is at least one of T cell claim 1 , B cell claim 1 , NK cell claim 1 , mast cell claim 1 , basophilic granulocyte claim 1 , acidophilic granulocyte claim 1 , neutrophil claim 1 , macrophage claim 1 , and dendritic cell.5. The method as claimed in claim 1 , wherein Z-BP is administered to the subject by oral administration claim 1 , transdermal administration claim 1 , nasal administration claim 1 , subcutaneous injection claim 1 , intravenous injection claim 1 , intramuscular injection claim 1 , peritoneal injection claim 1 , subcutaneous implantation claim 1 , interstitial implantation claim 1 , or two or more of the aforementioned administrations.6. The method as claimed in claim 5 , wherein Z-BP is administered to the subject as a wafer.7. The method as claimed in claim 1 , which is for treating cancer claim 1 , wherein the cancer is at least one of malignant brain tumor claim 1 , glioblastoma claim 1 , pancreatic cancer claim 1 , lung cancer claim 1 , and melanocytoma.8. The method as claimed in claim 1 , wherein Z-BP is administered at an amount ranging from about 30 mg/kg-body weight to about 2 claim 1 , ...

NOVEL PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATING LUNG INJURY

Disclosed are a novel pharmaceutical composition and use thereof, the novel pharmaceutical composition at least comprising an effective amount of mitochondria and at least one pharmaceutically acceptable carrier; the novel pharmaceutical composition is administered to an individual to send the mitochondria into injured or subject-to-oxidative-stress lung cells; thus treating or improving lung injury or related diseases thereof. 1. A pharmaceutical composition , comprising an effective amount of mitochondria and at least one pharmaceutically acceptable carrier.2. The pharmaceutical composition of claim 1 , further comprising an effective amount of melatonin.3. Use of the pharmaceutical composition of in the manufacture of a medicament for the treatment of lung injury and/or diseases related to lung injury.4. The use of claim 3 , wherein the diseases related to lung injury are selected from the group consisting of pneumonia claim 3 , atelectasis claim 3 , dyspnea claim 3 , pulmonary fibrosis claim 3 , and pulmonary edema.5. The use of claim 3 , wherein lung injury is acute respiratory distress syndrome. The present invention relates to a pharmaceutical composition and use thereof, particularly to a pharmaceutical composition containing mitochondria, which can be used to improve or treat lung injury.The lungs are an important organ in the respiratory system, and the organ has soft and elastic sponge-like structure containing 6 to 800 million alveoli. Gaseous exchange in humans is carried out in alveoli and the microvasculatures covered on the surfaces of alveoli. The lungs are a very fragile organ, in which acute lung injury may occur under some circumstances, such as lung transplantation, cardiopulmonary bypass, cardiopulmonary resuscitation, hypoxic respiratory failure, inhalation of smoke, and sepsis, which may lead to acute respiratory distress syndrome (Brun-Buisson C et al., 2004; Matthay M A et al., 2005; Rubenfeld G D et al., 2005; Phua J et al., 2009; Ailawadi ...

Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same

The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the β-amyloid protein (Aβ) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of Aβ in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism.

Method for controlling toxicity of metallic particle and low-toxicity composite of metallic nanoparticle and inorganic clay

The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets.

Neuronal epithelial cells differentiated by universal stem cells and the medium used and their differentiation methods

Semiconductor devices with composite etch stop layers and methods of fabrication thereof

Semiconductor devices with composite etch stop layers and methods of fabrication thereof. An semiconductor device with a composite etch stop layer includes a substrate having a conductive member, a first etch stop layer on the substrate and the conductive member, a second etch stop layer and a dielectric layer sequentially over the second etch stop layer, having a conductive layer therein down through the dielectric layer, the second etch stop layer and the first etch stop layer to the conductive member.

LED light mixing device

Novel pharmaceutical compositions and their use for the treatment of lung injury

Applications of butylidenephthalide

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.

以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法

本發明係揭露一種所揭以外源性粒線體為有效成份之組合物、其用途及修復細胞之方法，其中，該組合物係具有高度安全性，而藉由投予有效量之該組合物至一個體，得將外源性粒線體完整地送至細胞內，達到修復受損細胞、改善或預防細胞老化之功效，

新穎醫藥組合物及其用於治療肺損傷之用途

本發明係揭露一種新穎醫藥組合物及其用途，其中，該新穎醫藥組合物係至少包含有一有效量之粒線體及至少一藥學上可接受之載體。藉由投予該新穎醫藥組合物至一個體，將粒線體送入受損或面臨氧化壓力之肺部細胞內，能夠達到治療或改善肺部損傷或是與肺部損傷相關疾病之功效。

Selective pharmaceutical composition for the selective removal of undifferentiated universal stem cells and methods thereof

Cell proliferation apparatuses and uses thereof

Method for prevention or treatment of amyotrophic lateral sclerosis by administering gastrodin

Provided is a pharmaceutical composition including gastrodin and a use thereof for the prevention or the treatment of amyotrophic lateral sclerosis. The pharmaceutical composition is effective in reducing neuronal axon degeneration and neurofibromin accumulation, improving symptoms of amyotrophic lateral sclerosis and extending life of patients of amyotrophic lateral sclerosis.

Macrofagos modificados, composiciones y usos de los mismos.

La presente invención proporciona monocitos modificados, macrófagos modificados, composiciones farmacéuticas que comprenden los monocitos modificados o macrófagos modificados descritos en la presente y por lo menos un portador o excipiente farmacéuticamente aceptable. Se proporcionan usos de los monocitos modificados o los macrófagos modificados para el tratamiento y enfermedades musculoesqueléticas y que inducen la formación de cartílago. También se describen en la presente métodos de cultivo in vitro para generar los macrófagos modificados.

Modified macrophages, compositions and uses thereof

The present invention provides modified monocytes, modified macrophages, pharmaceutical compositions comprising the modified monocytes or modified macrophages described herein and at least one pharmaceutically acceptable carrier or excipient. Uses of the modified monocytes or the modified macrophages for the treatment of musculoskeletal diseases and inducing cartilage formation are provided. Also disclosed herein are in vitro culture methods for generating the modified macrophages.

Macrófagos modificados, suas composições e seus usos

MACRÓFAGOS MODIFICADOS, SUAS COMPOSIÇÕES E SEUS USOS. A presente invenção fornece monócitos modificados, macrófagos modificados, composições farmacêuticas compreendendo os monócitos modificados ou macrófagos modificados descritos neste documento e pelo menos um carreador ou excipiente farmaceuticamente aceitável. São fornecidos usos dos monócitos modificados ou dos macrófagos modificados para o tratamento de doenças musculoesqueléticas e indução da formação de cartilagem. Também são divulgados neste documento métodos de cultura in vitro para gerar os macrófagos modificados.

Modified macrophages, compositions and uses thereof

The present invention provides modified monocytes, modified macrophages, pharmaceutical compositions comprising the modified monocytes or modified macrophages described herein and at least one pharmaceutically acceptable carrier or excipient. Uses of the modified monocytes or the modified macrophages for the treatment of musculoskeletal diseases and inducing cartilage formation are provided. Also disclosed herein are in vitro culture methods for generating the modified macrophages.

Modified macrophages, compositions and uses thereof

選擇性去除未分化萬能幹細胞之醫藥組合物及其方法

本發明係在提供一種選擇性去除未分化萬能幹細胞之醫藥組合物，藉由提高未分化之萬能幹細胞內鉀離子之濃度以產生細胞毒性，據以使未分化之萬能幹細胞死亡，從而使由萬能幹細胞培養所得之特定細胞，不夾雜有未分化之萬能幹細胞。

Antibacterial nano silver particle/clay compound and the manufacturing method thereof

Method for prevention or treatment of amyotrophic lateral sclerosis by administering gastrodin

Provided is a pharmaceutical composition including gastrodin and a use thereof for the prevention or the treatment of amyotrophic lateral sclerosis. The pharmaceutical composition is effective in reducing neuronal axon degeneration and neurofibromin accumulation, improving symptoms of amyotrophic lateral sclerosis and extending life of patients of amyotrophic lateral sclerosis.

丁烯基苯酞之用途及將其製備爲醫藥組合物之方法

本發明所揭丁烯基苯酞係具有降低細胞內β類澱粉樣蛋白質濃度之能力，而能達到治療或預防神經退化性疾病之功效。據此，藉由本發明所揭醫藥組合物之製備方法，其將以高分子物質作為藥物載體，將為活性成分之丁烯基苯酞包覆於高分子物質中，用以減緩或降低丁烯基苯酞之細胞毒性，達到提昇醫藥組合物之安全性及治療或預防神經退化性疾病之功效。

Cell proliferation apparatuses and uses thereof

Provided is a cell proliferation apparatus, comprising (a) a device for cell storage or cell culture; and (b) a means or a unit to deliver an airflow to the device for cell storage or the cell culture. Also provide is an in vitro method to induce cell proliferation, by placing a plurality of cells in the cell proliferation apparatus described herein.

[UNK]

Application of z-butylidenephthalide for invigorating innate immune system

細胞胞器篩選裝置及以其採集細胞胞器之方法

本發明係提供一種細胞胞器篩選裝置及以其採集細胞胞器之方法，其中，該細胞胞器篩選裝置係透過設計流道組之尺寸，藉由壓力推擠細胞通過流道組，並且，流道壁給予細胞一反向阻力，使細胞被擠壓變形而破裂，將其內胞器釋放至流道內進行篩選，以達到收集目標胞器之功效。據此，藉由本發明所揭細胞胞器篩選裝置及以其採集細胞胞器之方法，係能夠達到大幅增加收集目標胞器之效率，並且分離出完整且未受污染之目標胞器之功效。

Cell proliferation apparatuses and uses thereof

Provided is a cell proliferation apparatus, comprising (a) a device for cell storage or cell culture; and (b) a means or a unit to deliver an airflow to the device for cell storage or the cell culture. Also provide is an in vitro method to induce cell proliferation, by placing a plurality of cells in the cell proliferation apparatus described herein.

持續維持運動神經元前驅細胞生長之方法及醫藥組合物

本發明係在於提供一種持續維持運動神經元前驅細胞生長之方法及醫藥組合物，其中，該持續維持運動神經元前驅細胞生長之方法透過將運動神經元前驅細胞培養於一由嗅神經髓鞘細胞所建構之環境中，使運動神經元前驅細胞長期地維持自我複製以及得以被誘導分化為成熟神經元之能力，據以有效地發揮對於運動神經元之保護作用。藉由本發明所揭方法得到之運動神經元前驅細胞，係能夠作為治療運動神經元受損相關疾病之醫藥組合物之有效成份。

Method and pharmaceutical composition for continuously maintaining growth of a motor neuron progenitor cell

This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron.